Neogen (NEOG): Persistent Losses Challenge Bullish Narratives Despite Attractive Price-To-Sales Valuation

Simply Wall St.10-10

Neogen (NEOG) is forecast to grow revenue at just 0.9% per year, lagging well behind the broader US market, which is expected to expand at 9.9% annually. The company remains unprofitable, with losses ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2574760121?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","is_english":true,"pubTime":"2025-10-10 14:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574760121","market":"sg","top_or_hot":-1,"title":"Neogen (NEOG): Persistent Losses Challenge Bullish Narratives Despite Attractive Price-To-Sales Valuation","media":"Simply Wall St.","content":"<div>\n<p>Neogen (NEOG) is forecast to grow revenue at just 0.9% per year, lagging well behind the broader US market, which is expected to expand at 9.9% annually. The company remains unprofitable, with losses ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/neogen-neog-persistent-losses-challenge-bullish-narratives-d\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neogen (NEOG): Persistent Losses Challenge Bullish Narratives Despite Attractive Price-To-Sales Valuation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeogen (NEOG): Persistent Losses Challenge Bullish Narratives Despite Attractive Price-To-Sales Valuation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-10 14:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/neogen-neog-persistent-losses-challenge-bullish-narratives-d><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neogen (NEOG) is forecast to grow revenue at just 0.9% per year, lagging well behind the broader US market, which is expected to expand at 9.9% annually. The company remains unprofitable, with losses ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/neogen-neog-persistent-losses-challenge-bullish-narratives-d\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEOG","symbol_name":"纽尔真检测","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/neogen-neog-persistent-losses-challenge-bullish-narratives-d","article_id":"2574760121","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-neog/neogen/news/neogen-neog-persistent-losses-challenge-bullish-narratives-d","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2574760121","pubTimestamp":1760076950,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Neogen (NEOG) is forecast to grow revenue at just 0.9% per year, lagging well behind the broader US market, which is expected to expand at 9.9% annually. The company remains unprofitable, with losses increasing at a rapid 90.4% annual pace over the past five years and no improvement in net profit margins. Looking ahead, Neogen is projected to remain in the red for at least the next three years. With discounted cash flow analysis off the table due to insufficient data, investors are likely to...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NEOG":"纽尔真检测"},"translate_title":"Neogen(NEOG)：尽管市销率估值颇具吸引力，但持续亏损挑战看涨叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEOG":1.5},"content_text":"Neogen (NEOG) is forecast to grow revenue at just 0.9% per year, lagging well behind the broader US market, which is expected to expand at 9.9% annually. The company remains unprofitable, with losses increasing at a rapid 90.4% annual pace over the past five years and no improvement in net profit margins. Looking ahead, Neogen is projected to remain in the red for at least the next three years. With discounted cash flow analysis off the table due to insufficient data, investors are likely to focus on the company’s value metrics and persistent unprofitability. See our full analysis for Neogen. The next section takes these headline numbers and examines how they fit with the prevailing narratives among investors and analysts. Some expectations may be confirmed, while others could face tough questions. See what the community is saying about Neogen NasdaqGS:NEOG Earnings & Revenue History as at Oct 2025 AdvertisementIntegration Hurdles Squeeze Margins  Integrating the 3M Food Safety business continues to be a drag, with high manual labor, elevated scrap, and excess costs causing gross and EBITDA margins to stay under pressure, according to management updates. Bears highlight that persistent integration shortfalls and ongoing inefficiencies are amplifying cost structures, which\n     force gross margin compression and limit near-term financial visibility, dampening enthusiasm for a turnaround, and suggest that operational improvements will only come gradually, extending margin weakness well into future quarters.    Portfolio Streamline Sets Stage for Quality Earnings  Neogen has shed lower-margin businesses in cleaners, disinfectants, and genomics, with a renewed focus on its core food safety and animal health operations. The analysts' consensus view sees this as a pivotal move, arguing that\n     the resulting product mix realignment and operational focus may lead to improved net margins down the line. Portfolio simplification allows for more resilient and higher-quality future earnings, but recent divestitures bring near-term risks from potential stranded costs and loss of revenue diversification, especially as transition-related costs persist for up to a year.   To see what’s behind this pivot and how the market weighs the pros and cons, take a look at the full range of analyst narratives for Neogen. 📊 Read the full Neogen Consensus Narrative.  Peer Discount Raises Value Debate  Neogen trades at a Price-To-Sales ratio of just 1.7x, cheaper than both the US Medical Equipment industry average (2.9x) and its peer average (4.2x), even as its current share price of $6.78 sits below the only allowed analyst target of $7.67. The consensus narrative suggests this gap is getting attention because\n     investors must weigh the relative value against peers versus the reality that Neogen remains unprofitable and is not expected by analysts to reach profitability within three years, so the debate centers on whether this lower valuation truly means opportunity or is simply a reflection of the uphill road to sustained profits.     Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Neogen on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. Looking at the data from another angle? Take a moment to craft your perspective and add a new narrative in just minutes. Do it your way A great starting point for your Neogen research is our analysis highlighting 1 important warning sign that could impact your investment decision. See What Else Is Out There Neogen’s persistent operating losses, challenged margins, and uncertain turnaround timeline make it difficult for the company to deliver the stable and reliable growth that many investors seek. If you want to focus on companies showing consistent revenue and earnings expansion, turn your attention to stable growth stocks screener for steadier alternatives designed to perform in various market conditions.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Neogen might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2574760121","isCrawlerRequest":true}